CDC Finalizes Cholera Vaccine Recommendation

The final recommendation was published in the CDC’s Morbidity and Mortality Weekly Report

According to a report, the CDC’s cholera vaccination recommendation is now final. The recommendation was published in the agency’s Morbidity and Mortality Weekly.

Vaxchora, a live oral cholera vaccine, was approved by the FDA in 2016. It is the only FDA-approved cholera vaccine in the United States, and is approved for use in adults ages 18 to 64.

The CDC says most travelers from the United States do not visit areas with active cholera transmission, but it can quickly kill people if it is not treated. The agency also recommends drinking safe water, cooking food thoroughly, and washing hands properly.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Analyze Incident Data and Maintain OSHA Compliance

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Industry Safe
comments powered by Disqus